TSE:ONC - Oncolytics Biotech Stock Price, News, & Analysis

C$2.23
0.00 (0.00 %)
(As of 06/14/2019 04:00 PM ET)
Today's Range
C$2.20
Now: C$2.23
C$2.24
50-Day Range
C$2.22
MA: C$2.43
C$2.61
52-Week Range
C$2.20
Now: C$2.23
C$8.25
Volume35,800 shs
Average Volume31,566 shs
Market CapitalizationC$45.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-6707380

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.66 per share
Book ValueC$0.30 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$45.26 million
Next Earnings Date8/2/2019 (Estimated)
OptionableNot Optionable

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Oncolytics Biotech (TSE:ONC) Frequently Asked Questions

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (TSE:ONC) released its quarterly earnings data on Thursday, May, 2nd. The company reported ($0.27) EPS for the quarter. View Oncolytics Biotech's Earnings History.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Friday, August 2nd 2019. View Earnings Estimates for Oncolytics Biotech.

What price target have analysts set for ONC?

1 brokerages have issued 12 month price targets for Oncolytics Biotech's stock. Their forecasts range from C$9.00 to C$9.00. On average, they expect Oncolytics Biotech's stock price to reach C$9.00 in the next twelve months. This suggests a possible upside of 303.6% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.

What is the consensus analysts' recommendation for Oncolytics Biotech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.

Has Oncolytics Biotech been receiving favorable news coverage?

Headlines about ONC stock have trended somewhat positive on Saturday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncolytics Biotech earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the immediate future. View News Stories for Oncolytics Biotech.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCYF), Resverlogix (RVX), Aptose Biosciences (APTO), Encana (ECA), Bombardier (BDRBF), Husky Energy (HUSKF), ProMetic Life Sciences (PLI), Microbot Medical (MBOT), Arsenal Energy (AEI) and First Majestic Silver (FR).

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Dr. Rita Laeufle, Chief Medical Officer

How do I buy shares of Oncolytics Biotech?

Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$2.23.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of C$45.26 million. View Additional Information About Oncolytics Biotech.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com/.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.


MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/15/2019 by MarketBeat.com Staff

Featured Article: Percentage Decliners

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel